Literature DB >> 14965265

NSAIDs and chemoprevention.

Chinthalapally V Rao1, Bandaru S Reddy.   

Abstract

Several epidemiological, clinical and experimental studies established nonsteroidal anti-inflammatory drugs (NSAIDs) as promising cancer chemopreventive agents. Long-term use of aspirin and other NSAIDs has been shown to reduce the risk of cancer of the colon and other gastrointestinal organs as well as of cancer of the breast, prostate, lung, and skin. Understanding the action of NSAIDs provides substantial insights into the mechanisms by which these unique agents regulate tumor cell growth and enable better strategies for prevention and treatment. NSAIDs restore normal apoptosis and reduce cell proliferation in human adenomatous colorectal polyps, experimental colonic tumors, and in various cancer cell lines that have lost critical genes required for normal function. NSAIDs, particularly selective cyclooxygenase-2 (COX-2) inhibitors such as celecoxib, have been shown to inhibit angiogenesis in cell culture and in rodent models of angiogenesis. Exploration of the multistep process of carcinogenesis has provided substantial insights into the mechanisms by which NSAIDs modulate these events. However, unresolved questions with regard to safety, efficacy, optimal treatment regimen, and mechanism of action currently limit the clinical application of NSAIDs to the prevention of polyposis in FAP patients. Moreover, the development of safe and effective NSAIDs for chemoprevention is complicated by the potential that rare, serious toxicity may offset the benefit of treatment with these drugs given to healthy individuals who have a low risk of developing the disease. Growing knowledge in this area has brought about innovative approaches using combine actions of NSAIDs with other agents that have different modes of action. It has also led to the development of nitric oxide-releasing NSAIDs, that induce tumor cell apoptosis and compensate for COX function, as a means of increasing efficacy and minimizing toxicity. There is growing optimism for the view that full exploration of the role of NSAIDs in the prevention and treatment of epithelial cancers will serve towards reducing of mortality and morbidity from various cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14965265     DOI: 10.2174/1568009043481632

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  70 in total

1.  Prevention of skin carcinogenesis by the β-blocker carvedilol.

Authors:  Andy Chang; Steven Yeung; Arvind Thakkar; Kevin M Huang; Mandy M Liu; Rhye-Samuel Kanassatega; Cyrus Parsa; Robert Orlando; Edwin K Jackson; Bradley T Andresen; Ying Huang
Journal:  Cancer Prev Res (Phila)       Date:  2014-11-03

Review 2.  NF-κB signaling in cancer stem cells: a promising therapeutic target?

Authors:  K Vazquez-Santillan; J Melendez-Zajgla; L Jimenez-Hernandez; G Martínez-Ruiz; V Maldonado
Journal:  Cell Oncol (Dordr)       Date:  2015-08-29       Impact factor: 6.730

3.  Next generation sequencing and functional pathway analysis to understand the mechanism of action of copper-tolfenamic acid against pancreatic cancer cells.

Authors:  Myrna Hurtado; Laszlo Prokai; Umesh T Sankpal; Blair Levesque; Rajasekhar Maram; Jaya Chhabra; Deondra T Brown; Raj K Gurung; Alvin A Holder; Jamboor K Vishwanatha; Riyaz Basha
Journal:  Process Biochem       Date:  2019-10-30       Impact factor: 3.757

4.  Binding of Cu(II) complexes of oxicam NSAIDs to alternating AT and homopolymeric AT sequences: differential response to variation in backbone structure.

Authors:  Sreeja Chakraborty; Esha Sehanobish; Munna Sarkar
Journal:  J Biol Inorg Chem       Date:  2012-01-20       Impact factor: 3.358

5.  2-Ethoxybenzamide stimulates melanin synthesis in B16F1 melanoma cells via the CREB signaling pathway.

Authors:  Kazuomi Sato; Ryosuke Ando; Honoka Kobayashi; Takashi Nishio
Journal:  Mol Cell Biochem       Date:  2016-09-16       Impact factor: 3.396

6.  Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis.

Authors:  Wei Qiu; Xinwei Wang; Brian Leibowitz; Hongtao Liu; Nick Barker; Hitoshi Okada; Naohide Oue; Wataru Yasui; Hans Clevers; Robert E Schoen; Jian Yu; Lin Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

7.  Diclofenac induced apoptosis via altering PI3K/Akt/MAPK signaling axis in HCT 116 more efficiently compared to SW480 colon cancer cells.

Authors:  Elif Damla Arisan; Zehragül Ergül; Gülnihal Bozdağ; Özge Rencüzoğulları; Ajda Çoker-Gürkan; Pınar Obakan-Yerlikaya; Deniz Coşkun; Narçin Palavan-Ünsal
Journal:  Mol Biol Rep       Date:  2018-11-08       Impact factor: 2.316

8.  Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.

Authors:  Altaf Mohammed; Naveena B Janakiram; Qian Li; Chang-In Choi; Yuting Zhang; Vernon E Steele; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-01

9.  Novel Therapeutics: NSAIDs, Derivatives, and Phosphodiesterases.

Authors:  Heather N Tinsley; Gary A Piazza
Journal:  Curr Colorectal Cancer Rep       Date:  2012-12

10.  Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.

Authors:  David L McCormick; Jonathan M Phillips; Thomas L Horn; William D Johnson; Vernon E Steele; Ronald A Lubet
Journal:  Cancer Prev Res (Phila)       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.